UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 367

Sortiert nach

Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?

The Lancet (British edition), 2023-07, Vol.402 (10399), p.348-350

Carraway, Hetty E

2023

Volltextzugriff (PDF)

Emerging therapies for acute myeloid leukemia

Journal of hematology and oncology, 2017-04, Vol.10 (1), p.93-93, Article 93

2017

Volltextzugriff (PDF)

Current and emerging strategies for management of myelodysplastic syndromes

Blood reviews, 2021-07, Vol.48, p.100791-100791, Article 100791

2021

Volltextzugriff (PDF)

Therapy for lower-risk MDS

Hematology, 2020-12, Vol.2020 (1), p.426-433

2020

Volltextzugriff (PDF)

Improving Overall Survival in Older Adults With Acute Myeloid Leukemia: Subpopulations Matter

Journal of clinical oncology, 2018-11, Vol.36 (32), p.3186-3188

Carraway, Hetty E

2018

Volltextzugriff (PDF)

Overview of the Management of Higher-Risk Myelodysplastic Syndromes

The cancer journal (Sudbury, Mass.), 2023-05, Vol.29 (3), p.160

2023

Volltextzugriff (PDF)

Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network

Leukemia, 2021-04, Vol.35 (4), p.1023-1036

2021

Volltextzugriff (PDF)

Vacuolization of hematopoietic precursors: an enigma with multiple etiologies

Blood, 2021-07, Vol.137 (26), p.3685-3689

2021

Volltextzugriff (PDF)

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Blood, 2014-07, Vol.124 (3), p.385-392

2014

Volltextzugriff (PDF)

Emerging treatment options for patients with high-risk myelodysplastic syndrome

Therapeutic Advances in Hematology, 2020-11, Vol.11, p.204062072095500-2040620720955006

2020

Volltextzugriff (PDF)

Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients

Current treatment options in oncology, 2024-06

2024

Volltextzugriff (PDF)

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer

Journal of clinical oncology, 2018-06, Vol.36 (18), p.1831-1839

2018

Volltextzugriff (PDF)

Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure

Hematology, 2016-12, Vol.2016 (1), p.470-477

Carraway, Hetty E

2016

Volltextzugriff (PDF)

Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci

Best practice & research. Clinical haematology, 2020-09, Vol.33 (3), p.101191-101191, Article 101191

2020

Volltextzugriff (PDF)

Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes

Blood, 2023-04, Vol.141 (14), p.1768-1772

2023

Volltextzugriff (PDF)

Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation

Nature communications, 2023-05, Vol.14 (1), p.3153-3153, Article 3153

2023

Volltextzugriff (PDF)

A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome

Haematologica (Roma), 2022-11, Vol.107 (11), p.2742

2022

Volltextzugriff (PDF)

IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors

Clinical cancer research, 2018-04, Vol.24 (7), p.1705-1715

2018

Volltextzugriff (PDF)

Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study

American journal of hematology, 2022-02, Vol.97 (2), p.174-184

2022

Volltextzugriff (PDF)

Recent progress in acute leukemia and myelodysplasia

Best practice & research. Clinical haematology, 2022-12, Vol.35 (4), p.101415-101415, Article 101415

2022

Volltextzugriff (PDF)

Molecular patterns identify distinct subclasses of myeloid neoplasia

Nature communications, 2023-05, Vol.14 (1), p.3136-3136, Article 3136

2023

Volltextzugriff (PDF)

Author Correction: Molecular patterns identify distinct subclasses of myeloid neoplasia

Nature communications, 2024-02, Vol.15 (1), p.1184-1184, Article 1184

2024

Volltextzugriff (PDF)

The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine

Leukemia, 2019-12, Vol.33 (12), p.2971-2974

2019

Volltextzugriff (PDF)

1 – 25 von 367

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(358)
Mit Volltextzugriff
(356)

Publikationsform

Artikel
(366)
Buchkapitel
(1)

Sprache

Englisch
(367)
Japanisch
(17)

Erscheinungsjahr

n.n

Thema

Science & Technology
(109)
Life Sciences & Biomedicine
(105)
Humans
(95)
Hematology
(70)
Oncology
(58)
Female
(41)
Male
(41)
Aged
(39)
Middle Aged
(35)
Leukemia
(26)
Adult
(25)
Mutation
(22)
Acute Myeloid Leukemia
(21)
Myelodysplastic Syndromes
(18)
Treatment Outcome
(17)
Dna Methylation
(16)
Leukemia, Myeloid, Acute - Drug Therapy
(16)
Leukemia, Myeloid, Acute - Genetics
(16)
Prognosis
(16)
Biological And Medical Sciences
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?

Emerging therapies for acute myeloid leukemia

Current and emerging strategies for management of myelodysplastic syndromes

Therapy for lower-risk MDS

Improving Overall Survival in Older Adults With Acute Myeloid Leukemia: Subpopulations Matter

Overview of the Management of Higher-Risk Myelodysplastic Syndromes

Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network

Vacuolization of hematopoietic precursors: an enigma with multiple etiologies

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients

Emerging treatment options for patients with high-risk myelodysplastic syndrome

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia

Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients

Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer

Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure

Myeloid neoplasms with germline predisposition: Practical considerations and complications in the search for new susceptibility loci

Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes

Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms

Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation

A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome

IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors

Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study

Recent progress in acute leukemia and myelodysplasia

Molecular patterns identify distinct subclasses of myeloid neoplasia

Author Correction: Molecular patterns identify distinct subclasses of myeloid neoplasia

The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine

Suchergebnisse filtern